Jump to content

User:Danno uk/Sandbox: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
DASHBot (talk | contribs)
m Removing fair use file(s), per WP:NFCC#9 (Shutoff | Log )
Line 1: Line 1:
{{Infobox company
{{Infobox company
|name = ALK-Abelló
|name = ALK-Abelló
|logo = [[Image:Merck-Logo.svg|120px|Merck KGaA's logo]] [[Image:EMD.svg|90px|EMD logo]]<!--World and United States/Canada logo-->
|logo = [[:Image:Merck-Logo.svg|120px|Merck KGaA's logo]]<!--Non free file removed by DASHBot--> [[:Image:EMD.svg|90px|EMD logo]]<!--Non free file removed by DASHBot--><!--World and United States/Canada logo-->
|type = [[Public company|Publicly traded]] [[Aktieselskab]] ({{OMX|CSE32679|ALK B}})
|type = [[Public company|Publicly traded]] [[Aktieselskab]] ({{OMX|CSE32679|ALK B}})
|foundation = 1668
|foundation = 1668

Revision as of 05:16, 9 February 2011

ALK-Abelló
Company typePublicly traded Aktieselskab (Nasdaq CopenhagenALK B)
Industrypharmaceuticals
Founded1668
FounderFriedrich Jacob Merck
Headquarters,
Key people
Jens Bager(President and CEO), Jørgen Worning (Chairman of the supervisory board)
ProductsEpipens, life science and performance chemicals, over-the-counter medicines, small molecules and biopharmaceuticals
RevenueDKK1.935 billion (2009)[1]
DKK175 million (2009)[1]
DKK118 million (2009)[1]
Number of employees
1,700 30 September 2010[2]
SubsidiariesMerck Serono
Websitewww.alk-abello.com

ALK-Abelló (Nasdaq CopenhagenALK B) is a Denmark-based pharmaceutical company producing vaccines for allergy and asthma.


Danish developer of diagnostic tools and treatments for allergys. Makes EpiPen for emergency treatment of allergic reactions to food or insect venom. Peers are Stallergenes, Genmab and Affitech. Partnered with Merck & Co in the US. Spun out of Christian Hansen in 2005.

main development product is hayfever treatment Grazax

http://www.alk-lifeline.co.uk/pages/faqs.aspx

  1. ^ a b c "Annual Report 2009" (PDF). Merck. Retrieved 2010-03-13.
  2. ^ Merck KGaA: Quartals-Finanzbericht 2010. dated 26 Oktober 2010